Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

3 Nov 2011 10:06

RNS Number : 4311R
Bank of America Merrill Lynch
03 November 2011
 



FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING

CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose INVESTEC LTD

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

principal trader is connected: INVESTEC LTD

(d) Date dealing undertaken: 02/11/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - ZAE000081949 Purchase 219,164 ZAR 47.80 ZAR 46.90

Common - ZAE000081949 Sale 219,164 ZAR 47.55 ZAR 47.03

(b) Derivatives transactions (other than options)

Class of Product description Nature of dealing Number of  Price per unit

relevant reference securities

security

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit (if

security applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 03/11/2011

Contact name: Balenkosi Dungeni

Telephone number: +44 20 7996 1639

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING

CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose Evolution Group Plc

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

principal trader is connected: INVESTEC LTD

(d) Date dealing undertaken: 02/11/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB0030221864 Purchase 14,409 GBP 0.83 GBP 0.82

Common - GB0030221864 Sale 10,444 GBP 0.83 GBP 0.81

(b) Derivatives transactions (other than options)

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB0030221864 Swap SHORT 7651 GBP 0.83

Common - GB0030221864 Swap SHORT 6400 GBP 0.82

Common - GB0030221864 Swap SHORT 358 GBP 0.82

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB0030221864 Swap LONG 1499 GBP 0.82

Common - GB0030221864 Swap LONG 1499 GBP 0.81

Common - GB0030221864 Swap LONG 7446 GBP 0.83

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 03/11/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING

CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose INVESTEC PLC

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

principal trader is connected: INVESTEC LTD

(d) Date dealing undertaken: 02/11/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB00B17BBQ50 Purchase 34,117 GBP 3.66 GBP 3.61

Common - GB00B17BBQ50 Sale 56,100 GBP 3.70 GBP 3.62

(b) Derivatives transactions (other than options)

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB00B17BBQ50 Swap SHORT 15358 GBP 3.66

Common - GB00B17BBQ50 Swap SHORT 4435 GBP 3.63

Common - GB00B17BBQ50 Swap SHORT 1365 GBP 3.63

Common - GB00B17BBQ50 Swap SHORT 267 GBP 3.63

Common - GB00B17BBQ50 Swap SHORT 84 GBP 3.61

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB00B17BBQ50 Swap LONG 4435 GBP 3.67

Common - GB00B17BBQ50 Swap LONG 1084 GBP 3.62

Common - GB00B17BBQ50 Swap LONG 1325 GBP 3.62

Common - GB00B17BBQ50 Swap LONG 2348 GBP 3.64

Common - GB00B17BBQ50 Swap LONG 3426 GBP 3.62

Common - GB00B17BBQ50 Swap LONG 5562 GBP 3.62

Common - GB00B17BBQ50 Swap LONG 8485 GBP 3.64

Common - GB00B17BBQ50 Swap LONG 16369 GBP 3.62

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit (if

security applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 03/11/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBXLFBFFFBFBZ
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.